Several major antiepileptic drugs are substrates for human P-glycoprotein.
about
Profiles of multidrug resistance protein-1 in the peripheral blood mononuclear cells of patients with refractory epilepsyA multi-system approach assessing the interaction of anticonvulsants with P-gpOntogeny of ABC and SLC transporters in the microvessels of developing rat brainP-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide.P-gp Protein Expression and Transport Activity in Rodent Seizure Models and Human EpilepsyDrug-Resistant Epilepsy: Multiple Hypotheses, Few AnswersECoG studies of valproate, carbamazepine and halothane in frontal-lobe epilepsy induced by head injury in the ratEnhanced brain delivery of lamotrigine with Pluronic(®) P123-based nanocarrierPgp-mediated interaction between (R)-[11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat dataCelecoxib treatment restores pharmacosensitivity in a rat model of pharmacoresistant epilepsy.Differences in the expression of endogenous efflux transporters in MDR1-transfected versus wildtype cell lines affect P-glycoprotein mediated drug transport.Pharmacogenetic evaluation of ABCB1, Cyp2C9, Cyp2C19 and methylene tetrahydrofolate reductase polymorphisms in teratogenicity of anti-epileptic drugs in women with epilepsyPolymorphism of ABCB1/MDR1 C3435T in children and adolescents with partial epilepsy is due to different criteria for drug resistance - preliminary results.Antiepileptic drug interactions - principles and clinical implications.Targeting the neurovascular unit for treatment of neurological disorders.Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein)Therapeutic epilepsy research: from pharmacological rationale to focal adenosine augmentation.Homeostatic bioenergetic network regulation - a novel concept to avoid pharmacoresistance in epilepsy.Co-administration of subtherapeutic diazepam enhances neuroprotective effect of COX-2 inhibitor, NS-398, after lithium pilocarpine-induced status epilepticus.Drug resistance in cortical and hippocampal slices from resected tissue of epilepsy patients: no significant impact of p-glycoprotein and multidrug resistance-associated proteinsCYP2C9, CYP2C19, and ABCB1 genotype and hospitalization for phenytoin toxicityPolymorphic Variants of SCN1A and EPHX1 Influence Plasma Carbamazepine Concentration, Metabolism and Pharmacoresistance in a Population of Kosovar Albanian Epileptic PatientsPharmGKB summary: phenytoin pathway.Factors Governing P-Glycoprotein-Mediated Drug-Drug Interactions at the Blood-Brain Barrier Measured with Positron Emission Tomography.In Vivo Imaging of Human MDR1 Transcription in the Brain and Spine of MDR1-Luciferase Reporter Mice.Regulation of ABC efflux transporters at blood-brain barrier in health and neurological disorders.The dual cyclooxygenase/5-lipoxygenase inhibitor licofelone attenuates p-glycoprotein-mediated drug resistance in the injured spinal cord.Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy.Pharmacogenetics of chronic pain and its treatment.Imaging of P-glycoprotein function and expression to elucidate mechanisms of pharmacoresistance in epilepsy.PET and SPECT radiotracers to assess function and expression of ABC transporters in vivoABC transporters P-gp and Bcrp do not limit the brain uptake of the novel antipsychotic and anticonvulsant drug cannabidiol in miceA novel positron emission tomography imaging protocol identifies seizure-induced regional overactivity of P-glycoprotein at the blood-brain barrierPilot PET Study to Assess the Functional Interplay Between ABCB1 and ABCG2 at the Human Blood-Brain Barrier(R)-[(11)C]verapamil is selectively transported by murine and human P-glycoprotein at the blood-brain barrier, and not by MRP1 and BCRP.The antiepileptic drug mephobarbital is not transported by P-glycoprotein or multidrug resistance protein 1 at the blood-brain barrier: a positron emission tomography study.Epilepsy pharmacogenetics.Association between ABCB1-T1236C polymorphism and drug-resistant epilepsy in Iranian female patients.The role of transporters in the pharmacokinetics of orally administered drugs.Transporter hypothesis of drug-resistant epilepsy: challenges for pharmacogenetic approaches.
P2860
Q28483667-32407F76-E155-434E-8CF9-ABCBE63099B8Q28533527-F408775B-F3EF-478A-BE4B-BA5BCF9D84D4Q28566257-727C605A-7174-4FCB-8556-7EDB532431A7Q33797745-C06AC060-AC41-460B-AC3F-FB57F6E585E1Q33875127-346168C2-32B1-47E8-B5F3-4AE33E200759Q33875271-5D0CCBB4-EA6E-41B2-984D-A992331B4675Q34005340-B431FD0C-E98C-4DFD-89CA-454FDBA1046FQ34075276-548EFEA1-5B98-4583-B160-044CB21FF607Q34100185-F917623F-2C03-4760-8692-635C78731A96Q34112939-96C0D199-C202-4FF5-BB65-A59FAB6DC35CQ34124847-EBA45B1A-E852-41CE-A1C8-E31AC4DDFE14Q34169804-F144B254-A498-4DEA-9709-E2B53ADD3F79Q34237989-1DDB8DAA-398E-4596-8107-955D5288AA92Q34402188-F0E72977-3096-4FFB-AE68-B1BB73F102F8Q34974827-543F8259-0219-4F3B-BC41-C663EF94818BQ34994901-0988A4EF-D0F0-4D88-AF1E-51E34AB53014Q34997511-9D55735F-A42A-43F1-A502-42F16003BF75Q35072901-928AC754-4384-4DAF-ACD6-DBF7BA159B66Q35078392-BE4CED36-CFEC-4421-A2B4-838ED631A4D2Q35094603-043CEC85-B668-4F35-AD58-86C7B4BC5B04Q35117277-1E05386B-2E54-40A8-A618-FB0A0BF63F34Q35837256-E69D81D7-1850-4957-9A30-60F81A0BB44CQ35950546-F84EDE7B-0334-4D05-B30C-F216E2C7AF02Q36049576-A540E341-2BB9-46AE-B0ED-27CE63C2E347Q36186153-BA3CB838-4B42-4368-B4E2-BB4A83BE1382Q36378047-83E50E15-EBE3-4E0E-8B4A-A5A9341881B5Q36590671-3BAED3EE-88FC-4739-AAE3-9DAA011F6A8DQ36603317-FBF177C6-5F7E-4A3F-8FD5-A1D53134AA00Q36900075-6052479F-6313-4B71-8E7B-662E56B05F3CQ36947636-C45A9DC4-2746-444C-8C5B-EB242BE87535Q36953090-3391CDB4-42C3-49C7-BDAC-685A7B18064CQ36954728-C4611CB5-E535-4278-9845-78DBEEB6C609Q36955931-94EEA14A-4D3A-433A-8F87-7C6FB608BE04Q37164563-76AB508C-BFB6-4284-B892-34DF9B37F796Q37177013-BEDE612A-6D91-4D14-853F-E18985EF5FBFQ37185659-DB93960E-9C35-4644-8C12-859A2DC28810Q37486720-E738C237-12B3-47D2-A6F1-AFFC2A7C6808Q37522302-5CABE1D1-0BEA-45CE-8AB2-91EA9B086439Q37537018-890F9C56-D2AC-4D5E-9DB1-E560ACFD8DE9Q37806763-89966CF8-AA9C-4333-A7DE-0E2E6910EE7E
P2860
Several major antiepileptic drugs are substrates for human P-glycoprotein.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Several major antiepileptic drugs are substrates for human P-glycoprotein.
@en
Several major antiepileptic drugs are substrates for human P-glycoprotein.
@nl
type
label
Several major antiepileptic drugs are substrates for human P-glycoprotein.
@en
Several major antiepileptic drugs are substrates for human P-glycoprotein.
@nl
prefLabel
Several major antiepileptic drugs are substrates for human P-glycoprotein.
@en
Several major antiepileptic drugs are substrates for human P-glycoprotein.
@nl
P2093
P1433
P1476
Several major antiepileptic drugs are substrates for human P-glycoprotein.
@en
P2093
Carlos Luna-Tortós
Maren Fedrowitz
Wolfgang Löscher
P304
P356
10.1016/J.NEUROPHARM.2008.08.032
P577
2008-09-11T00:00:00Z